Axolotl Biosciences
Axolotl Biosciences is a Victoria, BC-based University of Victoria spin-off that develops and sells xeno-free TissuePrint fibrin-based bioinks for 3D bioprinting of human tissue models to academic researchers and biotechnology companies.
- Company typePrivate
- Founded2020
- HeadquartersVictoria, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Axolotl Biosciences does
Axolotl Biosciences is a privately held Canadian biotechnology company founded in 2020 and headquartered in Victoria, British Columbia, as a spin-off from the University of Victoria's bioprinting research group. The company develops and sells TissuePrint, a research-grade, xeno-free, fibrin-based bioink for 3D bioprinting of human tissue models. Its product line includes a Low Viscosity (LV) formulation optimized for microfluidic bioprinters such as the Aspect Biosystems RX1, a High Viscosity (HV) formulation for extrusion-based bioprinters such as the CELLINK BIOX, and a complementary TissuePrint Crosslinker; all kits support human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), with constructs reported to maintain high cell viability for over a month in culture.
The company's technology has been validated through peer-reviewed publications in journals including ACS Biomaterials, Materials Today Chemistry, and Frontiers in Bioengineering, with demonstrated applications in drug screening, neural tissue engineering, glioblastoma tumor modeling, and neurocardiac systems. Axolotl sells its products directly through an e-commerce storefront with global shipping, priced at $500 per bioink kit and $100 per crosslinker, and supplements product sales with consulting services for bioprinting lab setup and bioink validation. Its core customers are academic researchers and biotechnology companies, and it has established technology partnerships with major bioprinter manufacturers (CELLINK, Aspect Biosystems, Allevi3D) and is supported by non-dilutive funding from Canadian programs including InnovateBC, Mitacs, MSFHR, IRAP, NSERC, and ventureLAB.
Axolotl Biosciences firmographics
Firmographics- Name
- Axolotl Biosciences
- Legal name
- Axolotl Biosciences
- Website
- https://axolotlbiosciences.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Axolotl Biosciences is a Victoria, BC-based University of Victoria spin-off that develops and sells xeno-free TissuePrint fibrin-based bioinks for 3D bioprinting of human tissue models to academic researchers and biotechnology companies.
- Ownership category
- akta.pro rank
Axolotl Biosciences industry classification
Industry- Product category
- Bioprinting Bioinks
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
Keywords
Where Axolotl Biosciences is headquartered
LocationHeadquarters
- HQ city
- Victoria
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Axolotl Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Bioink Product Sales: Direct e-commerce sales of TissuePrint bioink kits (LV and HV formulations) and crosslinkers to academic researchers and biotechnology companies globally.
- Consulting Services: Consulting services offered for bioprinting needs including setting up new lab spaces and testing bioinks on various bioprinters. Customers contact via email to discuss requirements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | TissuePrint-LV Kit - Low viscosity bioink for microfluidic bioprinters |
| Unit Pricing | Pay-as-you-go | TissuePrint-HV Kit - High viscosity bioink for extrusion bioprinters |
| Unit Pricing | Pay-as-you-go | TissuePrint Crosslinker - Xeno-free crosslinker component |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Axolotl Biosciences product offering
Product offeringCore offering
Axolotl Biosciences develops and sells fibrin-based bioink kits (TissuePrint-LV and TissuePrint-HV) and complementary crosslinkers used in 3D bioprinting of human tissue models. The xeno-free bioinks support multiple cell lines including human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), and are compatible with leading extrusion and microfluidic bioprinters. The company also offers consulting services for bioprinting lab setup and bioink testing.
Product overview
Axolotl Biosciences offers a portfolio of TissuePrint bioink products centered around their proprietary fibrin-based bioink technology for 3D bioprinting of human tissue models. The product line consists of two main bioink formulations—TissuePrint-LV (Low Viscosity) for microfluidic bioprinters and TissuePrint-HV (High Viscosity) for extrusion-based bioprinters—along with a complementary TissuePrint Crosslinker. Both bioink kits include components to make 5mL of bioink and 20mL of crosslinker. The company also provides consulting services for bioprinting needs. All products are research-grade, xeno-free, and designed to support hiPSCs, neural progenitor cells, and mesenchymal stem cells for drug development and tissue engineering applications.
Differentiator
Problem solved
Functional benefit
Brands
- TissuePrint: A fibrin-based bioink product line for 3D bioprinting of human tissue models, available in high viscosity (HV) and low viscosity (LV) formulations.
Products and services
- TissuePrint-LV Kit A research-grade, xeno-free, fibrin-based bioink with low viscosity formulation optimized for microfluidic-based bioprinters such as the Aspect Biosystems RX1. Supports hiPSCs, neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs). Each kit includes components to make 5mL of bioink and 20mL of crosslinker.
- TissuePrint-HV Kit A research-grade, xeno-free, fibrin-based bioink with high viscosity formulation optimized for extrusion-based bioprinters such as the CELLINK BIOX. Supports hiPSCs, neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs). Each kit includes components to make 5mL of bioink and 20mL of crosslinker.
- TissuePrint Crosslinker A research-grade, xeno-free crosslinker that pairs with both High Viscosity and Low Viscosity TissuePrint Bioinks. Used alongside bioink in the bioprinting process to create printable fibers for building 3D constructs. Recommended use of 20mL of crosslinker for every 5mL of bioink; each crosslinker kit includes components to make 20mL of crosslinker.
- Bioprinting Consulting Services Consulting services for bioprinting needs, including assistance setting up new lab spaces and testing bioinks on a wide range of bioprinters. Customers contact the company via email to discuss requirements.
Quantifiable outcome
- Cell viability maintained at 98% at day 7 post-printing with guggulsterone microspheres
- +2 more outcomes
Companies that use Axolotl Biosciences
Customer profileSegments2 records
Ideal customer profiles2 records
Axolotl Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
Feature7 records
Axolotl Biosciences partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Aspect BiosystemscoreAspect Biosystems is a bioprinter manufacturer whose RX1 microfluidic bioprinter is optimized for use with Axolotl Biosciences' TissuePrint-LV (Low Viscosity) bioink. Their technology is used in published research studies demonstrating the bioink's effectiveness for neural tissue engineering and neurocardiac system modeling.
- CELLINKcoreCELLINK is a bioprinter manufacturer whose BIOX extrusion-based bioprinter is optimized for use with Axolotl Biosciences' TissuePrint-HV (High Viscosity) bioink. The partnership enables compatibility between the bioink and CELLINK's bioprinting platform.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Axolotl Biosciences competitors and assessment
Company assessmentDirect peers
- Aspect Biosystems: Aspect Biosystems manufactures the RX1 microfluidic bioprinter for which Axolotl's TissuePrint-LV is the optimized bioink, while also developing its own tissue-therapeutic programs. It is a direct peer because it sells into the same 3D-bioprinting-for-tissue-modeling category and overlaps with Axolotl on bioink supply for the RX1 platform.
- Regemat3D: Regemat3D designs and sells extrusion-based bioprinters and develops its own line of bioinks and bioink components (including personalized bioinks for regenerative medicine). It is comparable to Axolotl because it competes in the bioink + bioprinter consumables market and serves similar academic and translational research customers.
- Rokit Healthcare: Rokit Healthcare develops 3D bioprinters, bioinks, and bio-fabrication workflows for regenerative medicine, including skin, cartilage, and bone tissue applications. It is comparable to Axolotl because it sells both bioprinters and proprietary bioinks into overlapping tissue-engineering and regenerative-medicine research markets.
- Organovo Holdings: Organovo is a 3D-bioprinting and tissue-engineering company that has historically sold bioprinted human tissue models and partnered on bioink development. It is comparable because it operates in the same 3D-bioprinting-for-human-tissue-modeling market that Axolotl's TissuePrint products serve.
- CollPlant Biotechnologies: CollPlant develops and commercializes recombinant human-collagen-based bioinks and 3D-bioprinting tissue products for regenerative medicine. It is directly comparable to Axolotl because both companies sell bioink consumables for 3D bioprinting of human tissue models and target researchers and therapeutic developers in tissue engineering.
- Poietis: Poietis develops laser-assisted 3D bioprinting platforms and bioink formulations for tissue engineering and regenerative medicine, including partnerships with major cosmetics and pharma players. It is a direct peer to Axolotl in the bioink/bioprinter-for-tissue-models category with overlapping customer use cases in drug discovery and tissue engineering.
- CELLINK (BICO): BICO/CELLINK is the dominant player in the 3D bioprinting ecosystem and sells both bioprinters (incl. BIOX, which Axolotl's TissuePrint-HV is optimized for) and a broad portfolio of competing bioinks. It is directly comparable because it operates in the same horizontal bioink market, targets overlapping academic/biopharma customers, and competes head-to-head on the same printer platforms.
- BioBots (now part of BICO/Allevi): Allevi (formerly BioBots, part of BICO) sells extrusion-based bioprinters (the Allevi 3D platform that Axolotl's TissuePrint is compatible with) and its own line of bioinks. It is a direct peer competing in the same academic/research bioink-and-bioprinter market that Axolotl addresses with TissuePrint.
Emerging players
- Brinter: Brinter is a smaller bioprinter manufacturer offering modular extrusion-based bioprinters and partnering with bioink developers. It is a peer because its printers are an alternative platform on which customers run bioinks, and its bioink-compatibility ecosystem partially overlaps with the multi-platform strategy behind TissuePrint.
Broad incumbents
- 3D Systems: 3D Systems is a large, publicly-traded additive-manufacturing company whose healthcare arm has historically included bioprinting and tissue-engineering activities. It is a broad incumbent comparable to Axolotl at the industry/category level — operating in 3D bioprinting — but with a far broader product portfolio and not specialized in fibrin-based bioinks.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Axolotl Biosciences social profiles
Digital presenceAxolotl Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Axolotl Biosciences leadership team
Management profileNumber of profiles
Profiles4 records
Axolotl Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Axolotl Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Axolotl Biosciences
What does Axolotl Biosciences do?
Axolotl Biosciences develops and sells fibrin-based bioink kits (TissuePrint-LV and TissuePrint-HV) and complementary crosslinkers used in 3D bioprinting of human tissue models. The xeno-free bioinks support multiple cell lines including human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), and are compatible with leading extrusion and microfluidic bioprinters. The company also offers consulting services for bioprinting lab setup and bioink testing.
Is Axolotl Biosciences a public or private company?
Axolotl Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Axolotl Biosciences founded?
Axolotl Biosciences was founded in 2020. It employs 1 to 10 people.
Where is Axolotl Biosciences based?
Axolotl Biosciences is headquartered in Victoria, Canada, in the North America region.
How does Axolotl Biosciences make money?
Two revenue lines are on record. Bioink Product Sales are the primary driver. The others are consulting Services.
Who are Axolotl Biosciences's main competitors?
Direct peers on record are Aspect Biosystems, Regemat3D, Rokit Healthcare, Organovo Holdings, CollPlant Biotechnologies, Poietis, CELLINK (BICO) and BioBots (now part of BICO/Allevi). Brinter is listed as an emerging player. 3D Systems is listed as a broad incumbent.
Does Axolotl Biosciences have an API?
No public API is recorded for Axolotl Biosciences.
What industry is Axolotl Biosciences in?
Axolotl Biosciences's product category is Bioprinting Bioinks. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 541714 and its SIC code is 2836.